Clinical Trial Update: Study of Radioiodine (131-I) Uptake Following Administration of Thyrogen and Hypothyroid States During Thyroid Hormone Withdrawal. [Phase 4]

View source ↗

Summary

Phase 4 trial update investigating uptake of radioactive iodine (I-131) after Thyrogen administration in hypothyroid states during thyroid hormone withdrawal.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hypothyroidism
• Thyroid Neoplasms

Drugs mentioned

• Radioiodine-131 (iodine-131 radiopharmaceutical)
• Thyrogen (thyrotropin alfa)

Snippet

Sponsor: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) | Conditions: Hypothyroidism, Thyroid Neoplasms | Phase 4 | Status: COMPLETED